Thus, it is conceivable that the combination of HD IL-2, to induce T-cell expansion, and PD-1 blockade, to eliminate tumor-induced immune suppression, might prove equally or more efficacious in select patients. The gene discussed is PDCD1; the disease is neoplasm.